New drug duo targets Hard-to-Treat cancers in early trial
NCT ID NCT05975073
Summary
This early-stage study is testing a new combination of two oral drugs, AMG 193 and IDE397, for adults with advanced solid tumors that have a specific genetic feature called MTAP-null. The main goals are to find the safest and most effective dose and to see if the treatment can shrink tumors, particularly in a type of lung cancer. It is for people whose cancer has progressed after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MTAP-NULL NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Astera Cancer Care
East Brunswick, New Jersey, 08816, United States
-
City of Hope National Medical Center
Duarte, California, 91090, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Community Health Network MD Anderson Cancer Center - North
Indianapolis, Indiana, 46250, United States
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Health Partners Cancer Center at Regions Hospital
Saint Paul, Minnesota, 55102, United States
-
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, 08035, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Monash Medical Centre
Clayton, Victoria, 3168, Australia
-
National Cheng Kung University Hospital
Tainan, 70403, Taiwan
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
New York University Grossman School of Medicine and New York University Langone Hospitals
New York, New York, 10016, United States
-
Next Oncology
Irving, Texas, 75039, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Prisma Health Upstate
Greenville, South Carolina, 29605, United States
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
-
The Queen Elizabeth Hospital
Woodville South, South Australia, 5011, Australia
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.